Indication
ARID1A
4 clinical trials
5 products
Clinical trial
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
NXP800Clinical trial
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-08-01
Product
JAB-2485Clinical trial
Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)Status: Recruiting, Estimated PCD: 2026-01-01
Product
BevacizumabProduct
NiraparibClinical trial
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A MutationStatus: Recruiting, Estimated PCD: 2025-01-01
Product
Tazemetostat